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I. ABSTRACT 
FOLLICULAR GROWTH AND SERUM ESTRADIOL CONCENTRATION AS 
PREDICTORS OF IN VITRO FERTILIZATION OUTCOME. Nicole Hausman, 
Antoni J. Duleba, and David L. Olive, Section of Reproductive Endocrinology, 
Department of Obstetrics and Gynecology, Yale University School of 
Medicine, New Haven, Connecticut. 
The outcome of in vitro fertilization and embryo transfer (IVF-ET) is 
influenced by multiple factors. Studies performed in populations with 
unspecified etiologies of infertility have suggested that the number of oocytes 
retrieved during a cycle of IVF may inversely correlate with subsequent 
fertilization and chance of pregnancy. The purpose of this study was to 
examine the relationships between pretransfer parameters in IVF-ET and the 
subsequent occurrence of pregnancy in patients assigned to individual 
diagnostic groups, with particular focus on patients with tubal disease. 
The study evaluated 466 stimulated cycles which proceeded to oocyte 
retrievals. In patients with tubal disease, the number of follicles measuring at 
least 12 mm on the day of human chorionic gonadotropin (hCG) 
administration correlated negatively with pregnancy rates: pregnancy rates 
were 28.3% for those with < 7 follicles and 8.7% for those with > 7 follicles (P = 
0.014). Comparable findings were observed when correlating pregnancy rates 
with estradiol level on the day of hCG administration: pregnancy rates were 
28.9% for those with estradiol ^ 1,000 pg/ml and 13.3% for those with 
estradiol > 1,000 pg/ml (P = 0.049). In contrast, the opposite trends were noted 
in patients with polycystic ovary syndrome and unexplained infertility, with 
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increasing pregnancy rates at both higher numbers of follicles and higher 
levels of estradiol. 
These findings demonstrate that ovarian response is a predictor of the 
success of IVF-ET in tubal disease patients, and that ovulation induction 
protocols may need to be individualized for each diagnostic group. 
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IL INTRODUCTION 
A. Infertility: Nature and Magnitude of the Problem 
Considering the complexity of the reproductive process, it is 
remarkable that 80% of couples achieve conception within one year of 
attempting pregnancy. Of the population attempting to conceive, a spectrum 
of fertility exists, extending from highly fertile couples to those with relative 
infertility. Infertility is usually defined as the inability of a couple practicing 
frequent intercourse without contraception to conceive a child within one 
year. It affects 15 to 20% of couples or approximately seven million people of 
reproductive age in the United States,^ and may be due to multiple etiologies 
in one or both partners. In fact, approximately 20% of infertile couples have 
more than one major cause (male factor, ovulatory dysfunction, or tubal- 
peritoneal disease) for their inability to conceive. Without therapy, 
spontaneous intrauterine pregnancies do occur in infertile couples, albeit at a 
substantially decreased rate; thus, treatments are pragmatically aimed at 
shortening the time to and increasing the likelihood of conception. With a 
thorough evaluation of the infertile couple and application of current 
treatments short of in vitro fertilization (IVF), 50 to 60% can be expected to 
conceive.^ For infertile couples experiencing failure of other available 
treatments, IVF with embryo transfer (ET) remains the last resort, with 
approximately 20% of those couples undergoing the procedure ultimately 
establishing a pregnancy. 
B. Diagnostic Considerations 
The precise incidence of the etiologic factors involved in infertility 
varies with the population studied. As an approximation, 15 to 20% of 
infertility cases are due to ovulatory dysfunction, 30 to 40% are due to pelvic 
I 
2 
factors (endometriosis, adhesions, or tubal disease), 30 to 40% are due to male 
factors (abnormal semen parameters), 5 to 10% are due to abnormal sperm- 
cervical mucous penetration or antisperm antibodies, and 10 to 15% are due 
to unexplained infertility, for which no cause can be elucidated using 
currently available tests.^ 
1. Tubal Factor Infertility 
During the past decade, the incidence of infertility caused by damage to 
the oviduct has increased, most probably due to an increased incidence of 
salpingitis. Obstruction of the oviduct may occur at either the proximal or 
distal portion, and may occasionally involve both regions simultaneously. 
The extent and location of the intrinsic and extrinsic tubal disease should be 
accurately determined by both hysterosalpingography and laparoscopy. The 
prognosis for conception after surgical tubal reconstruction depends heavily 
on the severity of tubal damage, with very low intrauterine pregnancy rates 
demonstrated in women with extensive pre-surgical obstruction. In these 
women, in vitro fertilization provides the most efficacious intervention.^ 
In the case of distal tubal obstruction, the hysterosalpingogram (HSG) 
aids in determining whether the tubal obstruction is complete or partial, the 
diameter of the hydrosalpinx (accumulation of serous fluid in the fallopian 
tube), and the appearance of the rugae. Beyond this, laparoscopy is usually 
necessary to determine the actual size of the hydrosalpinx, the thickness of 
the oviduct wall after distension with dye, and the presence or extent of 
pelvic adhesions. As previously stated, the prognosis for conception 
following distal tubal reconstruction correlates strongly with the extent of 
tubal damage present before surgery. If the fimbriae appear anatomically 
normal, but phimotic with only partial occlusion by adhesions, removal of 
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the adhesions by a fimbrioplasty procedure results in post-surgical conception 
rates on the order of 60 %.^ If the distal end is completely occluded and a 
salpingostomy (the creation of an artificial opening in a fallopian tube closed 
by inflammation) is necessary, conception rates following reconstruction drop 
to 30% with approximately 25% of these being tubal pregnancies.^ As such, it 
is only logical that a positive correlation exists between the degree of distal 
tubal damage prior to reconstructive surgery and the incidence of ectopic 
pregnancies following surgery.^ 
If no dye reaches the oviduct during performance of an HSG, the 
diagnosis of proximal tubal obstruction must be considered. Proximal tubal 
obstruction is most commonly due to damage resulting from infection, but 
may occasionally be caused by endometriosis. Spasm of the utero-tubal 
junction may occur during the HSG and should also be considered in the 
differential diagnosis. Microsurgical tubocornual reanastomosis in women 
with proximal tubal damage has resulted in term pregnancy rates of 
approximately 50% and ectopic rates less than 10%.^ 
As a rule, if conception does not occur within 6 to 12 months of 
surgical reconstruction and a repeat HSG reveals recurrent tubal obstruction, 
a second surgical procedure is not undertaken, due to dismal follow-up 
pregnancy rates. These patients are subsequently referred for in vitro 
fertilization.^ 
2. Endometriosis 
Although endometriosis is a benign disease, it often becomes 
progressive and chronic, with local infiltration and wide dissemination. By 
definition, endometriosis is the presence and growth of the glands and 
stroma of the uterine lining in an aberrant location. Although the age- 
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specific incidence or prevalence of endometriosis can only be approximated, it 
is believed that the prevalence of the disease has been increasing over the past 
25 years. Estimates reveal that endometriosis is present in 5 to 15% of 
laparotomies performed on women of reproductive age, while the prevalence 
increases to 30 to 45% in those who are infertile. Heterotopic endometrial 
tissue grows under the cyclic influence of ovarian hormones, thus explaining 
onset and symptoms during the reproductive years. Most commonly, 
patients with endometriosis are women in their mid-30's, nulliparous, 
involuntarily infertile, with symptoms of dysmenorrhea and pelvic pain. 
The etiology of endometriosis, while not accurately elucidated, has been 
hypothesized to involve many factors, including retrograde menstruation, 
vascular dissemination, metaplasia, genetic predisposition, immunologic 
defects, and hormonal influences. No single theory adequately explains the 
many manifestations of the disease.^ 
The underlying pathophysiology producing infertility in women with 
endometriosis remains largely unknown, although a relationship between 
the severity of the disease and infertility has been established. Olive et al. 
reported that approximately 65% of women with mild endometriosis 
conceived without treatment, while only 25% and 0% of women with 
moderate and severe endometriosis, respectively, became pregnant with 
expectant management alone.^ In the presence of moderate or severe disease 
with extensive adhesions involving the oviducts, the causal relationship 
between endometriosis and infertility seems clear. However, in patients with 
minimal or mild disease, a causal relationship between infertility and 
endometriosis has not yet been established.^ 
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3. Polycystic Ovary Syndrome 
The most common cause of chronic anovulation is the polycystic ovary 
syndrome (PCO), a complex endocrine disorder consisting of 
hyperandrogenism and anovulation, involving dysfunction of the 
hypothalamus, pituitary, ovaries, adrenals, and peripheral adipose tissues. 
One of the hallmarks of PCO is the relative elevation of luteinizing hormone 
(LH) over follicle-stimulating hormone (FSH), with exaggerated pulse levels 
of LH in association with low normal levels of FSH. Explanations for the 
relative disparity of LH to FSH have invoked hypothalamic-pituitary 
involvement with a central disturbance in the frequency and amplitude of 
gonadotropin releasing hormone (GnRH). As such, factors that affect GnRH 
secretion must also be considered in the pathogenesis of PCO, including 
endogenous opioids, neurologic factors, and prolactin/ 
A strong association between galactorrhea, hyperprolactinemia, and 
PCO has long been recognized. Many reports have suggested that 
hyperprolactinemia in PCO is caused by the inhibitory effect of increased 
estrogen levels on the dopaminergic system/ Support of this concept is 
demonstrated, in part, by a sustained reduction in circulating LH levels 
achieved in PCO patients administered dopamine/ Further studies have 
shown a synchrony between endogenous pulses of LH and prolactin/ with 
bromocriptine (a dopamine agonist) induced reductions of prolactin and LH 
secretion in PCO patients/ Moreover, hyperprolactinemic women 
demonstrate significantly higher levels of dihydroepiandrosterone-sulfate 
(DHEAS) than normal controls, with treatment of the elevated prolactin 
resulting in DHEAS reductions/ 
Bilateral polycystic ovaries represent the sine qua non of PCO. 
Typically, follicles in the ovaries are arrested in follicular development. 

6 
measure approximately two to eight mm in diameter and appear as a "string 
of pearls" located beneath a smooth, glistening capsule. In contrast with 
normo-ovulatory patients, follicles in PCO patients are usually found to be in 
varying stages of growth and atresia, without production of a dominant 
follicle/ Erickson et al., demonstrated that arrested follicular development in 
PCO was not due to an inherent defect in ovarian steroidogenesis. In this 
study, the follicles of PCO patients were capable of producing normal levels of 
estrogen from the precursor androstenedione in the presence of appropriate 
levels of gonadotropin secretion or the addition of exogenous FSH/0 
Polycystic ovary syndrome often presents with excessive hirsutism and 
hyperandrogenism. The adrenal gland, as a producer of approximately 50% of 
peripheral androstenedione (the remaining 50% being of ovarian origin), 
may be significantly involved in the pathogenesis of a proportion of PCO 
patients. Congenital or acquired blocks in the androgen steroidogenesis 
pathway may lead to elevations in levels of precursor hormones with 
androgenizing potential, resulting in hirsutism, acne, oligomenorrhea, 
infertility, and other findings similar to those in PCO. However, most 
investigators agree that this PCO-like appearance in congenital adrenal 
hyperplasia is distinct from "classical" PCO. The adrenal gland is normally 
regulated by a tight feedback loop involving the hypothalamus and pituitary. 
As such, the association between adrenocorticotropic hormone (ACTH) and 
PCO has become a subject of much interest/ Although PCO patients usually 
have higher levels of LH, dihydroepiandrosterone (DHEA), DHEAS, 
testosterone, and androstenedione than healthy women, ACTH levels are 
similar in both groups. ^ This finding introduces the possibility that adrenal 
androgen production in PCO patients may be due to altered adrenal 
responsiveness to ACTH, rather than to alterations in ACTH production/ 
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Of great importance in the pathogenesis of PCO in many patients are 
the peripheral extraglandular sources of circulating estrogens. Although the 
majority of estrogens originate from the ovaries and adrenal glands, 
aromatization of androgens to weaker estrogens occurs in the skin, brain, and 
adipose tissue. Because PCO patients are often overweight, the increased 
peripheral aromatization of elevated androgens may lead to excessive levels 
of estrogens. The increased estradiol levels have, in turn, been shown to 
correlate with both high LH/FSH ratios^ and reductions in hypothalamic 
dopamine levels in women with PCO.^ 
The most common medication used in the ovulation induction of 
patients with PCO is clomiphene citrate (CC; Clomid), a partial agonist of 
estrogen. Using CC, approximately 80 to 90% of PCO patients achieve 
ovulation, with 40 to 50% of these women ultimately conceiving. In patients 
with poor ovulatory response to CC, the treatment of choice is usually 
human menopausal gonadotropin (hMG)/ 
Ovulation induction in patients with PCO is associated with an 
increased risk of multiple births and ovarian hyperstimulation syndrome 
(characterized by massive ovarian enlargement and third-space fluid 
accumulation), possibly due to the presence of multiple small follicles and 
elevated LH and estrogen levels. Therefore, in PCO patients, pregnancy rates 
are maximized and complication rates minimized by administering 
gonadotropins in small doses over a longer period of time than in the 
ovulation induction of other infertility patients/ 
4. Male Factor Infertility 
In approximately 30 to 40% percent of infertile couples, male factors are 
at least partially responsible for the inability to conceive/^ In one third of 
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infertile couples, male-factor abnormalities are detected in the man alone, 
while in an additional 20% of cases, etiologic factors are diagnosed in both the 
man and woman. As part of a standard evaluation, a semen analysis 
should be undertaken in all couples presenting with infertility. Although 
there is wide variation between patients and repeat samples from the same 
patients in terms of volume, number, and motility of sperm, normal 
guidelines for each of these parameters are well established.^ Typical 
abnormalities detected by semen analysis are low sperm concentration 
(oligospermia), decreased motility (asthenospermia), decreased normal forms 
(teratospermia), and increased semen viscosity. ^ If an abnormality is found, 
a repeat analysis should be performed two to three months later in order to 
determine the actual presence or absence of a male factor. It is considered 
clinically inappropriate to designate a male patient as infertile based upon a 
single semen analysis.^ Examination of the male with abnormal semen 
analyses may reveal a varicocele or ductal obstruction (both of which are 
surgically correctable), an immunologic disorder, a hormonal disturbance, or 
after thorough negative evaluation, an idiopathic etiology. When treatment 
of the male partner is unsuccessful, insemination with split ejaculates, 
intrauterine insemination with washed sperm, or combinations of these 
modalities with ovulation induction may be effective. In cases of severe 
sperm abnormalities, conventional IVF is often useful, given its ability to 
combine high concentrations of motile sperm with oocytes in a small volume 
of medium, optimizing the possibility of fertilization. Fertilization rates are 
uniformly reduced in male factor infertility. Although embryo transfer rates 
are approximately 50%, pregnancy rates per transfer are similar to those for 
other diagnostic etiologies of infertility.^ 
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5. Unexplained Infertility 
The term "unexplained infertility" is reserved for couples experiencing 
infertility of greater than two years' duration in the face of a normal, 
complete evaluation, including documentation of normal ovulation, normal 
semen parameters, normal sperm-mucus interaction and post-coital test, and 
normal uterus and tubes by HSG and laparoscopy.*^ A study conducted by 
Barnea et al. demonstrated that among patients with unexplained infertility 
diagnosed by such an evaluation, the average duration of infertility was 39 
months, with 34% achieving pregnancy within six months of study 
registration and 80% within five years.*® 
Many explanations for the etiology of unexplained infertility have been 
postulated, including changes in the "ovarian reserve" and other occult 
abnormalities. An increase in the proportion of couples assigned to the 
unexplained category of infertility may, in part, be a consequence of changing 
childbearing behavior, with more women delaying childbearing to older 
ages.*'7 With older chronological female age may come alterations in the 
ovarian response, as indicated by a study performed on 51 women aged 35 or 
older with unexplained infertility. In this study, a clomiphene challenge test 
was used to assess fertility, with women subsequently divided into two 
groups: those with diminished ovarian reserve (with post-challenge FSH 
levels elevated to a mean of 39 mIU/ml) and those with adequate reserve 
(with post-challenge mean FSH levels of 12 mIU/ml). Treatment consisting 
of ovulation induction, timed intercourse, or insemination resulted in 
pregnancy in 42% of women with adequate reserve, while only 5% of those 
with diminished reserve became pregnant. *^ Other explanations for 
unexplained infertility may include occult dysfunction of ovum production 
and release, defective corpus luteum function, defects in sperm transport and 
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function (with otherwise normal semen parameters), subtle uterine or tubal 
defects including dysfunctional ovum pick-up and transport, "silent" 
infection in either the seminal fluid or the female genital tract (chlamydia, 
mycoplasma, and ureaplasma being commonly associated with subfertility), 
and immunologic infertility. ^ 
Treatment for true unexplained infertility, as confirmed by a more 
detailed evaluation (ultrasound evaluation of follicular dynamics, sperm 
function assays, evaluation of subtle tubal, uterine, and pelvic factors, tests for 
occult infectious agents, and immunologic testing) usually includes 
ovulation induction and assisted reproductive technology in the form of 
gamete intrafallopian transfer (GIFT) or IVF 
C. Ovulation Induction in IVF 
The early use of superovulation cycles in IVF established that success 
was principally determined by the number of embryos transferred into the 
uterine cavity. In essence, the replacement of three or more healthy embryos 
optimized the likelihood of achieving an ongoing pregnancy. Replacement 
of more than three embryos increases the likelihood of multiple pregnancies 
while not increasing the pregnancy rate.-^O Given this information, it has 
become usual practice to recover atleast four or five good quality oocytes in 
order to be reasonably sure of the replacement of three healthy embryos.^ * 
Although natural cycle IVF may be of value in a limited number of patients, 
it has been predominantly superseded by superovulation cycles for assisted 
reproduction in an attempt to maximize the generation of large numbers of 
mature oocytes. What follows is a review of normal folliculogenesis in the 
unstimulated cycle and an overview of the ovulation induction procedures 
commonly used in IVF. 
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1. Folliculogenesis 
Ovarian function in the normal or stimulated cycle rests upon 
communication, of either a stimulatory or inhibitory nature, between the 
hypothalamus, pituitary, and ovary. During supraphysiologic stimulation of 
the ovaries for in vitro fertilization, the pharmacology of exogenous 
hormone therapy markedly alters the relationships between these endocrine 
organs, affecting the dynamics of follicular development.^ 
During the embryonic period, primordial germ cell populations are 
established that will later give rise to oocytes. Just prior to birth, the two to 
four million primary oocytes formed during fetal life reach prophase of the 
first meiotic division. The primordial follicle then consists of this primary 
oocyte covered by a single layer of granulosa cells.A portion of the 
primordial follicles begin to grow or undergo atresia as soon as they are 
formed, while others enter a quiescent state until puberty.^ Reactivation of 
quiescent primordial follicles, follicular development, and oocyte atresia 
appear to punctuate a continuous process in the ovary, beginning 
immediately after the first follicles form and progressing until the end of the 
reproductive period.^ 
Hodgen proposes a two-tiered ovarian mechanism operative in 
follicular development. At the first tier, specific factors, both intraovarian 
and extraovarian, govern the progressive diminution of the cohort of 
developing follicles to the ovulatory quota of each cycle. This regulation of 
cohort size only operates, however, when circulating gonadotropins (FSH and 
LH) exceed minimal tonic levels. At the second tier, ovarian steroidal and 
nonsteroidal hormones negatively feed back to inhibit gonadotropin 
secretion, thus controlling circulating gonadotropins at appropriate tonic 
levels. The first and second tiers of the proposed mechanism are intimately 
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connected, such that changes in the components of one tier may drastically 
alter activities of the second. For example, it is hypothesized that if 
circulating gonadotropin levels are far above the tonic set-point, then first tier 
ovarian mechanisms become impaired, resulting in superovulation. 
Therefore, multiple follicular development occurs as a result of both 
increased gonadotropin availability and the overriding of early follicle 
selection mechanisms.^ 
During each cycle, primordial follicles are "recruited" and depart from 
the resting pool to undergo a well-characterized pattern of development,^ 
termed by Schwartz the "trajectory of follicle growth".^ Growing follicles are 
vulnerable to atresia at any point along this "trajectory", making recruitment 
an obligatory, but decidedly preliminary, step in the selection of a dominant 
follicle from the developing cohort.-^ 
Under the influence of FSH in the natural cycle, the number of 
granulosa cells in the primordial follicle increases and the follicle matures 
into a primary or preantral follicle. As the number of granulosa cells 
increases, the production and secretion of estradiol from these cells increases, 
representing the first sign of functional maturation.^' ^4 Estradiol, in turn, 
stimulates preantral follicle growth, prevents follicular atresia, and 
potentiates the effects of FSH on the granulosa cells. The follicle destined to 
become dominant secretes the greatest amount of estradiol; in fact, almost 
80% of the approximately 500 mg of estradiol produced daily just prior to 
ovulation originates from the dominant follicle. The elevated estradiol 
levels increase the density of FSH receptors on the follicle surface, ultimately 
causing a surge in the mitotic activity of the granulosa cells. Moreover, the 
rising concentration of estradiol exerts a negative feedback effect on the 
release of FSH from the pituitary, halting the development of the less FSH 
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sensitive non-dominant follicles. The dominant follicle, in contrast, 
continues to develop due not only to its increased highly vascularized theca 
cells, allowing more FSH to reach the receptors, but also to its increased 
density of FSH receptors. As the granulosa cells proliferate, LH receptors 
appear on their surface membranes in response to FSH and estradiol; when 
LH binds to the receptors, granulosa cell proliferation ceases and the cells 
begin to secrete progesterone. 23 in essence, the follicle destined to ovulate 
plays a pivotal role in regulating the size of the ovulatory quota, inhibiting 
the development of other follicles in the cohort, and becoming "dominant" 
about a week prior to ovulation. Interestingly enough, this dominant follicle 
continues to thrive in a physiologic milieu it has itself made inhospitable for 
others.^ 
Just prior to ovulation, the dominant follicle attains, on average, a 
mean diameter of approximately 19.5 mm, with a range of 18 to 25 mm. The 
maximal size of the dominant follicle can vary among different women, as 
well as in the same woman in different cycles. Rapidly rising estradiol levels, 
in combination with the small increase in progesterone produced by the 
dominant follicle, serve as the signal to the hypothalamic-pituitary axis that 
the follicle has matured sufficiently for ovulation. At midcycle, the 
substantial estradiol increase stimulates LH secretion and the small 
preovulatory progesterone increase stimulates FSH secretion, culminating in 
an LH and FSH surge. The midcycle LH surge is responsible for initiating the 
ovulatory process, germinal vesicle disruption, and completion of metaphase 
I of meiosis. LH stimulates synthesis of prostaglandins and proteolytic 
enzymes, both of which aid in follicular rupture; FSH stimulates production 
of plasminogen activator, producing plasmin to detach the cumulus from the 
granulosa cells, assisting egg extrusion during follicular rupture. It has been 
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determined that ovulation occurs approximately 24 hours after the estradiol 
peak, 12 to 16 hours after the LH peak in serum, and about 32 hours after the 
initial elevation in LH level. Once the oocyte is extruded during follicle 
rupture, the corpus luteum forms and produces progesterone under the 
influence of LH. After ovulation, the increasing levels of estradiol and 
progesterone exert a negative feedback effect on FSH and LH, respectively.^ 
Although the precise mechanisms of folliculogenesis during ovulation 
induction have still not been fully elucidated, it is generally postulated that 
follicular recruitment occurs in much the same fashion as it does during the 
natural cycle. The most notable difference between stimulated and non- 
stimulated cycles remains, quite simply, the sheer number of follicles 
recruited for ovulation, with higher yields for stimulated cycles. 
2. Clomiphene Citrate 
Until recently, the most frequent ovarian stimulation regimen used in 
assisted conception was the combination of clomiphene citrate and exogenous 
gonadotropins (hMG). The purpose of such a regimen is to override the 
estrogen-driven negative feedback on endogenous gonadotropin secretion 
that occurs in a natural cycle. In essence, CC causes a mild hypersecretion of 
pituitary gonadotropins, thus stimulating the recruitment of a number of 
small follicles. Exogenous gonadotropins may be administered thereafter to 
sustain the growth of this cohort of recruited follicles, achieving multiple 
synchronous follicular development. Multiple follicular development causes 
increased estradiol levels, resulting in positive feedback elevations in LH. 
The best success rates with the CC/hMG combination have been achieved 
with monitoring for the endogenous LH surge, which may occur in the late 
follicular phase. If the endogenous LH surge remains undetected, ovulation 
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prior to oocyte recovery or the collection of postmature oocytes may occur. 
The occurrence of the LH surge is not predictable by follicle size once the 
leading follicle exceeds 15 mm in diameter, by the absolute level of estrogen, 
or by the rate of estrogen rise. If the LH surge is successfully detected, used to 
time oocyte recovery, and supported by the administration of human 
chorionic gonadotropin (hCG), the patient's clinical performance through an 
assisted conception cycle is optimized. The criteria for the administration of 
hCG for ovulation induction in CC/hMG cycles are the detection of the 
spontaneous LH surge or one or more follicles reaching 18-20 mm in 
diameter.If hCG is given too late, the most advanced follicles may yield 
postmature (or fragmented) eggs of low potential viability; conversely, if hCG 
is injected too early, the eggs may be immature.^ Oocyte recovery is timed 
approximately 32 hours after 5,000-10,000 IU of hCG is administered.^ 
Early results with CC/hMG demonstrated a clinical pregnancy rate of 
35% following the transfer of three embryos, clinical pregnancy rates per 
transfer of 25%, and a "take-home baby rate" of approximately 15%. A 
comparison of patients who became pregnant after embryo transfer and those 
whose embryos failed to implant revealed that patients who established a 
clinical pregnancy had both significantly lower urinary LH output in the 2 
days prior to ovulation induction and lower plasma LH levels in the late 
follicular phase. More specifically, higher late follicular phase LH levels 
correlated with compromised oocyte quality and fitness, reduced 
implantation rate, and early pregnancy loss. The degree of gonadotropin 
hypersecretion induced with clomiphene appears to vary between 
individuals and between cycles within the same individual.^ 
The consequences of high late follicular phase LH levels may be 
explained by consideration of the mechanism of oocyte maturation and 
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ovarian paracrinology. One hypothesis states that the natural midcycle LH 
surge promotes the degradation of the gap-junctional communication system 
in the granulosa cell layers, thus impeding the passage of oocyte maturation 
inhibitor(s) from the follicle wall to the oocyte.^® A second hypothesis 
postulates that the LH surge stimulates the expression of maturation- 
inducing factors by the granulosa cells.^ it has been shown that high basal 
LH concentrations, as are present in individuals with PCO, may have direct 
negative influences upon oocyte viability in ovarian stimulation for 
IVf30,31/ although other evidence has failed to generate support of this.32 
3. Gonadotropin Releasing Hormone Agonists 
In patients who show inappropriately elevated levels of LH during 
superovulation with CC/hMG, improvements in follicular recruitment, 
fertilization rates, and pregnancy rates can be achieved through an inhibition 
of LH by administration of gonadotropin releasing hormone (GnRH) 
agonists. Upon first exposure to the GnRH agonist, a massive release of the 
pituitary gonadotropins LH and FSH occurs for approximately two to four 
days, followed by the requisite feedback inhibition of LH synthesis and 
depletion of its readily releasable form. The membrane-bound GnRH agonist 
stimulates receptor internalization and degradation, thus decreasing receptor 
numbers; moreover, the continued occupation of the pituitary gonadotropin 
receptors maintains a lowered sensitivity to endogenous GnRH. The 
consequence of prolonged GnRH agonist use is lowered circulating levels of 
LH (and FSH, to a smaller degree) as well as inhibition of ovulation. After 
cessation of GnRH analogue administration, normal pituitary function is 
only recovered as de novo receptor synthesis occurs. As the gonadotropin 
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receptors become sensitive to endogenous GnRH, circulating levels of LH and 
FSH are restored.^ 
Ovulation induction strategies combining GnRH analogues and 
exogenous gonadotropins (hMG or pure FSH) fall into three basic categories: 
long, short, and ultra-short protocols. In the long protocol, a GnRH agonist is 
administered for a period of 8 to 21 days, beginning in the early to mid-luteal 
phase of the preceding cycle, achieving a temporary state of hypogonadotropic 
hypogonadism. Once desensitization of the pituitary gonadotrophs to 
endogenous GnRH is completed, the GnRH agonist dose is reduced to a 
maintenance level, prolonging ovarian quiescence and suppression of 
circulating gonadotropins while preventing an endogenous LH surge. 
Adequate superovulation may then be achieved by the daily administration 
of exogenous gonadotropins, with approximately 10 days of stimulation being 
adequate for sufficient ovulation induction and estrogen priming of the 
endometrium. Due to the suppression of endogenous LH secretion, 
luteinization rarely occurs until an ovulation-inducing dose of hCG is 
27 given. 7 
The short and ultra-short regimes both make use of the initial release 
or "flare" phase of GnRH agonist action, stimulating follicular recruitment 
and early development^ and reducing the amount of gonadotropin 
required.^ As the pituitary gonadotrophs become desensitized by prolonged 
GnRH agonist administration and hyposecretion of endogenous 
gonadotropins occurs, continued follicular growth is supported by exogenous 
gonadotropins. In order to take advantage of the release phase, both short 
protocols must commence in the early follicular phase, by day two or three of 
menstruation. It is important to note, however, that the onset of menses 
does not uniformly correlate with the complete demise of the corpus luteum 
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from the previous cycled As such, the corpus luteum may be "rescued" by 
the endogenous gonadotropin release following agonist administration, 
causing elevated levels of progesterone through the follicular phase at a time 
when the endometrium should be proliferating without exposure to 
progestational influences.*^ 
The use of GnRH agonists, in combination with exogenous 
gonadotropins, significantly increases the chance of pregnancy when 
compared to treatment with clomiphene citrate combined with hMG. LH 
suppression in the late follicular phase results in improved oocyte and 
embryo quality.^ 
D. Factors Affecting the Outcome of IVF 
1. Age 
The outcome of in vitro fertilization and embryo transfer (IVF-ET) is 
influenced by multiple factors. According to a prospective study undertaken 
by Hughes et al., the single factor most significantly detrimental to pregnancy 
rates in IVF was advancing female age, with a linear decline beginning at 25 
years.34 Studies evaluating the effect of increasing female age on IVF 
outcome have yielded varying estimates of pregnancy rates, with women 
aged 40 years or more achieving conception in anywhere from 3.8 %34 to 
23%35 of cycles. Moreover, patients in the higher age group demonstrate a 
decreased ability to maintain pregnancies, with spontaneous abortion rates 
observed to be as high as 60%.35 It is generally accepted that aging female 
infertility patients have considerably worse IVF outcomes than younger 
diagnosis-matched patients. 
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2. Male Factor Infertility 
Studies performed on patients with male factor infertility have shown 
a distinct relationship between sperm factors and IVF-ET outcome. Sperm 
motility and morphology, concentration of sperm in the insemination 
medium, and sperm vitality have all correlated with fertilization rate.^6/ 37 
3. Embryo Quality 
Although definitions of embryo quality and embryo grading systems 
differ among IVF centers, both morphologic appearance and cleavage rate 
have been clearly correlated with pregnancy rate. Puissant et al. defined a 
semi-quantitative, non-invasive method for scoring embryos based upon the 
quantity of anucleate fragments expelled by the embryos at cleavage and the 
embryo development rate. Healthy appearing embryos were more often 
associated with pregnancy, and in particular, with multiple pregnancy.^ 
4. Patterns of Estradiol Secretion 
Pregnancies resulting from IVF-ET cycles have been associated with 
wide ranges of estradiol values. There is considerable controversy regarding 
appropriate levels of estradiol during the various phases of IVF. As shown by 
Jones et al., women classified as high, normal, or low responders with respect 
to estradiol levels showed only small differences in pregnancy rates. It was 
therefore concluded that the absolute estradiol level was generally a poor 
predictor of success in IVF.^9 However, in a study conducted by Dor et al., 
changes in the daily pattern of estradiol during the peri-hCG period were 
found to be a reliable predictor of outcome in cycles of women stimulated 
with CC/hMG or hMG alone. Although there were no differences in the 
mean daily follicular phase estradiol levels between the pregnant and control 
groups, failure of fertilization was associated with significantly lower estradiol 
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levels during the days just prior to and following the administration of hCG. 
In fact, 96% of the women in the study who achieved conception 
demonstrated either rising or plateauing estradiol levels on the day following 
hCG (seen in only 62.5% of control cycles), while 37.5% of the women in the 
control, non-pregnant group had decreasing estradiol levels during the same 
time period. If declining estradiol is interpreted as indicative of follicular 
atresia, then it is plausible that lower estradiol levels in the post-hCG period 
could result in a poorer quality oocyte and a correspondingly diminished 
likelihood of fertilization and conception.^® In contrast to the Dor et al. 
study, Howies et al. showed that plasma levels of estradiol four and six days 
after oocyte recovery during CC/hMG stimulated cycles were significantly 
higher in patients who did not become pregnant than in the pregnant 
group,^ supporting the possibility that elevated estradiol levels after hCG 
administration may be detrimental to establishing a pregnancy. 
5. Endometrial Receptivity 
The establishment of pregnancy through the use of IVF depends not 
only on the generation of multiple embryos of good quality, but also upon the 
presence of a receptive endometrium to allow and maintain embryonic 
implantation. While stimulating adequate numbers of oocytes for 
fertilization, ovulation induction simultaneously causes the production of 
supraphysiologic levels of estradiol and progesterone from the multiple 
follicles and subsequent corpora lutea. The extraordinarily high steroid levels 
encountered in the early luteal phase during ovarian stimulation must 
undoubtedly influence the quality and receptivity of the endometrium. In 
fact, some studies suggest that the balance or ratio of steroid hormones, and 
their subsequent influence on the endometrium, may be aberrant in women 
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who fail to implant.^* Along these same lines, conflicting discussion 
abounds in the literature regarding the necessity for or detriment of high 
progesterone output during the luteal phase of stimulated cycles. 
Supplementation of the luteal phase with exogenous progesterone and 
stimulation of endogenous progesterone production by the corpus luteum 
with hCG are popular practices in IVF, indicating the belief that higher luteal 
phase progesterone may positively impact endometrial quality and 
implantation success.Studies performed to date, however, have not 
consistently demonstrated that luteal phase support increases subsequent 
pregnancy rates. 
6. Oocyte Quality 
The quality of the oocyte obtained in an IVF program has been shown 
to be one of the keys to determining oocyte maturity and embryo quality, both 
of which influence normal fertilization and subsequent development. 
Premature or postmature insemination of oocytes have been demonstrated to 
result in a higher incidence of failed or abnormal fertilization.^ Despite this, 
the optimal diameter of the preovulatory follicle has not been precisely 
determined. Most likely, the optimal oocyte measures between 18 and 20 
mm in diameter before ovulation and 26 to 28 mm soon after ovulation 
begins, around the time of oocyte retrieval.^ At the time of follicular 
puncture, the retrieval of smaller follicles frequently occurs. It has been 
shown, however, that oocytes derived from large follicles are more efficient 
with respect to resumption of meiosis and fertilizing ability. In a study by 
Bomsel-Helmreich et al., no nuclear maturation was found in ova of follicles 
measuring less than 16 mm, highlighting the delay in maturation among 
smaller follicles.^ 
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7. Number of Oocytes Retrieved 
Many studies have examined the relationship between the number of 
oocytes retrieved during a cycle of IVF and subsequent fertilization and 
outcome of embryo transfer. Pellicer et al. demonstrated that the fertilization 
rate was significantly decreased in groups of patients producing 11 or more 
oocytes in comparison with patients producing smaller numbers of oocytes at 
the time of collection.-^ Testart et al. have also found a lower fertilization 
and pregnancy rate when the number of follicles increases, with the 
proportion of normal embryos per recovered oocyte inversely related to the 
degree of ovarian response.-^ In another study by Sharma et al., the clinical 
pregnancy rate per embryo transfer showed a linear rise when up to 5 oocytes 
were collected, with the rate plateauing at higher oocyte numbers. Moreover, 
this study demonstrated that the success of implantation (defined as the 
number of gestational sacs + number of embryos transferred x 100) was 
highest when 7 to 9 oocytes were retrieved and more than 60% of these 
fertilized; when 10 or more oocytes were collected, the implantation rate 
revealed a progressive decline, even though the fertilization rate remained 
above 60%.^7 
8. Number of Preovulatory Follicles 
The relationship between the number of follicles and the occurrence 
and quality of pregnancy has also received attention. Testart et al. 
demonstrated the influence of ovarian response on oocyte suitability for 
transfer in cycles with the transfer of one, two, or three embryos. In this 
study, the number of punctured follicles, recovered oocytes, and cleaved 
embryos had no significant effect on the success of embryo transfer in patients 
who received one, two, or three embryos, although the proportion of ongoing 
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pregnancies decreased when the number of follicles increased. Moreover, a 
higher oocyte cleavage rate was demonstrated among patients with one to 
four follicles (termed a "moderate" response) than among those producing 
five or more follicles.^ in a study conducted by Forman et al., the pregnancy 
rate in a population combining all infertility diagnoses was shown to decrease 
from 52% with <, 2 follicles measuring more than 14 mm in diameter on the 
day of hCG administration to 33% with 3 to 4 follicles and 20% with 9 or more 
follicles detected (PcO.Ol). Surprisingly, the authors of this study concluded 
that the number of follicles measuring greater than 14 mm at the time of hCG 
did not correlate with pregnancy rate, although the data suggest otherwise.^ 
Of the studies cited here, it is apparent that a relationship exists 
between the number of preovulatory follicles and the outcome of ET, 
observed both as a trend^S and as a statistically significant result. 49 However, 
it is essential to note that these correlations were demonstrated in 
populations combining patients with many etiologies of infertility. Whether 
the relationship between ovulatory response and pregnancy rate is borne out 
in groups of patients with specific diagnoses has not yet been determined. 
III. STATEMENT OF PURPOSE 
The purpose of the study proposed here is an examination of the 
relationships between pretransfer parameters in IVF-ET and the subsequent 
occurrence of pregnancy in patients assigned to individual diagnostic groups, 
with particular focus on patients with tubal disease. 

IV. METHODS 
A. Overview of the Population 
The study evaluated 505 randomly selected cycles of IVF performed 
between February 1984 and November 1993. Cases used in the study included 
those with successful ovarian response, fertilization, and embryo transfer, as 
well as those in which no fertilization or transfer of retrieved oocytes 
occurred. The only cycles omitted during chart review were those dropped 
before adequate ovarian stimulation could be completed due to poor response 
(few follicles, low estradiol), or an exaggerated response to stimulation 
(excessive follicular development, high estradiol, risk of ovarian 
hyperstimulation syndrome). 
B. Ovulation Induction Protocols 
Controlled ovarian hyperstimulation was primarily achieved with 
human menopausal gonadotropin (hMG; Pergonal) formulated as ampoules 
containing 75 IU each of FSH and LH, or with pure FSH containing 75 IU of 
FSH alone (pure FSH/Metrodin). In the majority of cycles included in the 
study, hMG or pure FSH was used either alone or in combination with each 
other and/or with a GnRH agonist (Lupron). The remainder of cases were 
stimulated using Clomid protocols, either alone or in combination with 
hMG. The daily doses of hMG/FSH administered to each patient per cycle 
varied and were adjusted according to diagnosis, folliculogenic response, and 
past cycle experience. 
Monitoring was performed both ultrasonographically and 
biochemically. Baseline ultrasound scans were performed before hMG/FSH 
administration to detect ovarian cysts and fibroids, as well as to ensure 
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adequate ovarian suppression. Monitoring beyond this baseline scan was 
then individualized, with subsequent endovaginal ultrasound exams and 
estradiol levels dictating changes in management. 
On the day of hCG administration, each patient had an estradiol and 
progesterone level drawn and an endovaginal ultrasound scan performed. 
The standard criteria for the administration of hCG (10,000 IU) included 
ultrasonographic detection of at least 2 follicles measuring greater than 16 
mm in diameter, and an estradiol level not exceeding 3,000 pg/ml. Oocyte 
retrievals were carried out approximately 32 hours after hCG administration. 
No oocytes were excluded from the insemination protocol. All oocytes 
were examined 16 to 18 hours after insemination and again at 48 hours, just 
prior to embryo transfer; if, at these times, oocyte cleavage or two pronuclei 
were visualized, fertilization was considered to have occurred. Upon 
examination, embryos were scored to indicate quality, maturity, and 
suitability for transfer. The embryo scoring system used in cycles included in 
this study was defined as follows: grade 1 was assigned to unfragmented 
embryos with regular blastomeres; grade 2 was assigned to embryos with 
minor fragments and regular blastomeres; remaining embryos with evidence 
of irregular blastomeres or more severe fragmentation were assigned a grade 
of 3. Embryos were transferred 2 days after oocyte retrieval. Variable 
numbers of embryos were transferred and frozen in each cycle, based upon 
the number and quality of oocytes and embryos produced, as well as upon the 
patient's age, past reproductive history, and plans for fetal reduction in the 
case of multiple gestation. 
Plasma radioimmunoassays to detect embryonic hCG secretion were 
performed on the twelfth day after embryo transfer. Clinical pregnancy was 
documented by detection of fetal heart activity on ultrasound scan. 
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C. Etiologic Definitions 
Patients were considered to have tubal factor infertility if the fallopian 
tubes were shown to be blocked, either unilaterally or bilaterally, by HSG or 
laparoscopy. All cases of severe tubal scarring or encasement in adhesions 
evident upon laparoscopy were accompanied by abnormal 
hysterosalpingograms, and as such, were easily interpretable as tubal factor 
infertility. Patients with recurrent ectopic pregnancies and pelvic adhesions 
diagnosed by laparoscopy, with or without HSG documentation of definitive 
blockage, were also considered to have tubal disease. Patients were 
determined to have "pure" tubal disease in the presence of a normal semen 
analysis, regular ovulations documented by a history of regular cycles, 
positive LH predictor kits, or biphasic basal body temperature (BBT) charts, 
and the absence of endometriosis and PCO. 
The diagnosis of polycystic ovary syndrome was made based upon a 
combination of a number of factors, including a history of oligo- or 
anovulation, an ultrasound scan revealing enlarged ovaries with multiple 
small follicles, hirsutism, and hyperandrogenism indicated by increased 
DHEA, DHEAS, and free testosterone levels. Based on the rationale that the 
presence of PCO dominated the clinical picture of patients with this disorder, 
patients were assigned to the PCO diagnostic group with or without the 
presence of other etiologies of infertility. 
Patients diagnosed with endometriosis were designated as such based 
upon laparoscopic documentation of the presence or absence of ectopic 
endometrial implants, categorized according to the American Fertility Society 
classification.50 Stage I of the classification was designated as minimal 
endometriosis, stage II as mild, stage m as moderate, and stage IV as severe, 
for the purposes of this study. Patients grouped in the "pure" endometriosis 
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category were required to have endometriosis documented by the previously 
described classification, and an absence of tubal disease, male factor, and PCO; 
"pure" endometriosis patients were, however, allowed to have other 
diagnoses not expressly evaluated in this study (luteal phase defects or 
hypothalamic anovulation). 
The diagnosis of male factor was applied to couples based upon 
stringent seminal criteria. In order to be judged subfertile, the semen analysis 
was required to demonstrate a sperm count less than 20 million/ml, sperm 
motility less than 40%, or a semen volume less than 1.5 ml. In addition, 
abnormal creatinine kinase parameters were considered convincing 
indications of male subfertility,5*'^ even when accompanied by otherwise 
normal semen parameters. "Pure" male factor patients were designated as 
such if clinical records indicated a presence of male factor with an absence of 
tubal disease, PCO, or endometriosis. 
Patients were assigned to the unexplained infertility group in the 
presence of persistent infertility without evidence of ovulatory dysfunction, 
tubal disease, endometriosis, or male factor. In addition, all unexplained 
infertility patients had confirmed normal luteal function, determined by an 
endometrial biopsy taken on day 26 or 27 of the natural cycle (the glands and 
stroma of the tissue biopsied must be histologically in-phase with the cycle 
day upon which it was sampled, as determined by the onset of next menses). 
D. Statistical Methods 
Unless stated otherwise, all variables were described as means +_ 
standard error of the mean. Differences between means were tested by 
Student's f-test. Correlations between variables in each cycle were analyzed 
using Pearson's correlations. 
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To assess the significance of heterogeneities in frequency distributions 
among groups and subgroups, chi-square tests were used. If the expected 
frequency in any subgroup was less than five, the Fisher exact test (two-tailed) 
was used instead. 
E. Contributions 
The original study design and concept was provided by Dr. David L. 
Olive and Dr. Antoni J. Duleba. Data collection was performed by Nicole 
Hausman. Statistical analysis was performed by Nicole Hausman under the 
supervision of Dr. Duleba. 
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V. RESULTS 
A. Population Distribution 
The initial population examined in this study consisted of 208 women, 
from which data on 505 IVF cycles were obtained. The study focused on the 
analysis of patients who underwent controlled ovarian hyperstimulation. In 
order to examine such patients, stimulated cycles (N=466 cycles) were 
separated from natural (N=18 cycles), egg donor (N=5 cycles), and sperm 
donor (N=16 cycles) cycles; the demographics and distribution of each of these 
subdivisions are shown in Table 1 and Figure 1, respectively. As shown in 
Table 2 and Figure 2, the general (stimulated) population was further 
subdivided by etiology of infertility into: tubal disease (N=106 cycles), PCO 
(N=34 cycles), endometriosis (N=36 cycles), male factor (N=28 cycles), and 
unexplained infertility (N=36 cycles), comprising 23%, 7%, 9%, 6%, and 8% of 
the general population, respectively. The remaining 47% (N=226 cycles) of 
the general population consisted of patients with more than one of the above 
primary diagnoses or other diagnoses (luteal phase defects, hypothalamic 
anovulation). The mean ages of patients in the individual diagnostic 
categories were not significantly different. 
The distribution and demographics of the various ovarian stimulation 
protocols used in the general population are summarized in Table 3. Among 
those who underwent ovarian stimulation, 22.5% of patients received 
hMG/FSH only, 71.3% received hMG/FSH and Lupron, and 6.3% received 
Clomid, with or without hMG. 
B. Outcome of IVF 
The means of individual variables assessed during the IVF cycles in 
each diagnostic category are presented in Table 4. The average duration of 
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gonadotropin administration in individual diagnostic categories ranged from 
8.19 to 9.58 days of hMG/FSH stimulation, and from 21.88 to 31.65 ampoules 
of hMG/FSH used. Of note, the cycles comprising the PCO category 
demonstrated the longest period of hMG/FSH stimulation (9.58 + 0.66 days) 
with the lowest amount of hMG/FSH used (21.88 ± 1.21 ampoules), 
corresponding to the widely accepted practice of slow, low dose stimulation of 
PCO patients. 
The average number of oocytes retrieved in each diagnostic category 
also varied widely, ranging from 7.79 in the male factor group to 12.18 in the 
PCO group. The average number of retrieved oocytes in PCO patients was 
49% greater than the number of oocytes retrieved in the general population; 
however, this increase was associated with only a 20% increase in the number 
of fertilized oocytes in the PCO group above the general population. 
Furthermore, PCO patients had the lowest probability of fertilization, 
averaging 47.59%. Patients in the tubal disease population had the highest 
percentage of oocyte fertilization, averaging 74.44%. 
The average number of transferred embryos ranged from 2.65 in those 
with male factor to 4.08 in those with endometriosis. In addition, the average 
grade of transferred embryos ranged from 1.85 in patients with PCO to 2.14 in 
patients with endometriosis, noting that lower grades were associated with 
higher quality, as described in the Methods section. Thus, patients with PCO 
and tubal disease had the highest quality of transferred embryos, with grades 
of 1.85 and 1.86, respectively. 
Clinical pregnancy rate was 17.6% for the general population, 19.8% in 
the tubal disease category, 20.6% in patients with PCO, 13.9% in those with 
endometriosis, 10.7% in the male factor group, and 19.4% in patients with 
unexplained infertility (Figure 3). 
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The mean number of follicles measuring £ 12 mm in diameter on the 
day of hCG administration was 7.51 in the general population, 7.34 in the 
tubal disease category, 9.39 in patients with PCO, 8.78 in those with 
endometriosis, 8.16 in the male factor group, and 7.31 in patients with 
unexplained infertility (Figure 4). 
The average estradiol levels measured on the day of hCG 
administration ranged from 1,275 pg/ml in the male factor group to 2,122 
pg/ml in the PCO group (Figure 5). 
C. Correlations 
The correlations between the number of follicles measuring >12 mm 
in diameter on the day of hCG administration and several of the variables 
analyzed in each cycle of IVF are shown in Table 5. In general, positive 
correlations were observed between the number of follicles and estradiol 
levels, number of oocytes retrieved, number of oocytes fertilized, and number 
of embryos transferred. A significant negative correlation was observed 
between the number of follicles >12 mm and the percentage of oocytes 
fertilized in the general and tubal disease groups, with the stronger 
correlation seen in the tubal disease group. While a slight negative 
correlation between these parameters was noted in the endometriosis and 
unexplained infertility categories, these effects were not statistically 
significant. Furthermore, there was a trend in the tubal disease group toward 
an increase in the grade of transferred embryos (i.e. decrease in embryo 
quality) with increasing number of follicles measuring £ 12 mm. This 
correlation was not seen in any other diagnostic category. 
The correlations between the number of oocytes retrieved and several 
of the parameters studied in each cycle of IVF are shown in Table 6. The 
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duration of administration of hMG/FSH and total amount of hMG/FSH used 
per cycle appeared to correlate negatively with the number of oocytes 
retrieved in almost all diagnostic groups. In all diagnostic groups, positive 
correlations were observed between the number of oocytes retrieved and 
estradiol level, number of oocytes fertilized, and number of embryos 
transferred. Statistically significant negative correlations between the number 
of oocytes retrieved and the percentage of oocytes fertilized were observed in 
both the tubal disease and endometriosis populations. Furthermore, the 
embryo transfer grade increased with increasing number of oocytes retrieved 
for both tubal disease and PCO patients, although neither relationship was 
statistically significant. 
D. Influence of the Number of Follicles on Pregnancy Rate 
Figure 6 presents pregnancy rate in the individual diagnostic categories 
as a function of the number of follicles measuring >12 mm in diameter on 
the day of hCG administration. The patients in each diagnostic category were 
stratified into two groups: those producing <, 7 follicles measuring £ 12 mm 
and those producing > 7 follicles measuring £12 mm. In the general 
population, there was virtually no difference in pregnancy rate as a function 
of number of follicles detected on the day of hCG, with an 18.4% pregnancy 
rate (46 of 250 cases) for < 7 follicles and a 16.5% pregnancy rate (35 of 212 
cases) for > 7 follicles. However, in the tubal disease group, a statistically 
significant decline in pregnancy rate was demonstrated between the two 
stratifications, with pregnancy rates of 28.3% (17 of 60 cases) for patients with <, 
7 follicles and 8.7% (4 of 46 cases) for patients with > 7 follicles (Fisher exact 
test, P = 0.014). In contrast, the PCO and unexplained infertility groups 
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displayed the opposite trends, with increasing pregnancy rates at higher 
numbers of follicles, although these findings were not statistically significant. 
E. Influence of the Estradiol Level on Pregnancy Rate 
Figure 7 presents the difference in pregnancy rates in the individual 
diagnostic categories as a function of estradiol level measured on the day of 
hCG administration. In the general population, there was only a minimal 
difference observed in the pregnancy rate as a function of estradiol level, with 
a 16.9% pregnancy rate (33 of 195 cases) for estradiol <, 1,000 pg/ml and an 
18.0% pregnancy rate (46 of 256 cases) for estradiol > 1,000 pg/ml. In contrast, 
in the tubal disease group there was a significant decline in pregnancy rate at 
higher estradiol levels, with pregnancy rates of 28.9% (13 of 45 cases) for 
estradiol < 1,000 pg/ml and 13.3% (8 of 60 cases) for estradiol > 1,000 pg/ml (3^ 
= 3.889, P = 0.049). The opposite trend was observed in the unexplained 
infertility group, where a higher pregnancy rate was seen in patients with 
estradiol > 1,000 pg/ml. 
F. Distribution of Pregnancy Rates 
Table 7 shows the distribution of pregnancy rates by diagnosis, as a 
function of increasing number of follicles measuring £ 12 mm on the day of 
hCG administration. The patients in each diagnostic category were stratified 
according to the number of follicles detected, and analyzed in increments of 
two follicles. The table demonstrates a wide variation in patterns between the 
different diagnoses, with a peak in the pregnancy rate at higher numbers of 
follicles for PCO, but in the middle of the range for the unexplained infertility 
group. The histograms shown in Figures 8A and 8B illustrate the effect of 
increasing numbers of follicles > 12 mm on the pregnancy rate in the general 
and tubal disease populations. In the general population (Figure 8A), a 
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relatively uniform distribution is apparent, with little change in the 
pregnancy rate as the number of follicles increases. The tubal disease group 
(Figure 8B), however, demonstrates higher pregnancy rates at the lowest 
numbers of follicles, with rates gradually declining as the numbers of follicles 
increase. 
G. Factors Influencing Pregnancy in Tubal Disease 
The averages of variables analyzed in each cycle of IVF are presented in 
Table 8 for the tubal disease population, as a function of successful or 
unsuccessful embryo transfer. The duration of administration of hMG/FSH 
and the total amount of hMG/FSH used per cycle were comparable in those 
who achieved pregnancy and in those who did not. Mean estradiol levels in 
those achieving pregnancy were lower than in those who did not, although 
this trend was not statistically significant. The number of follicles measuring 
>12 mm on the day of hCG administration was significantly lower in the 
pregnant than in the non-pregnant patients (P = 0.017); a similar trend was 
evident between these two groups when the number of follicles measuring ^ 
16 mm on the day of hCG administration was evaluated, although this 
relationship was not significant. Furthermore, the number of oocytes 
retrieved and the number of oocytes fertilized were each lower in the 
pregnant than in the non-pregnant women with tubal disease. In contrast, 
the percentage of oocytes fertilized was higher in women who became 
pregnant. Although the average number of embryos transferred in the 
pregnant and non-pregnant groups were virtually identical, the average grade 
of the embryos transferred was significantly better in the pregnant group (P = 
0.007). 
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Figure 9 shows the average number of transferred embryos in tubal 
disease patients who became pregnant, as a function of the number of follicles 
measuring £ 12 mm on the day of hCG administration. The patients in the 
pregnant group were stratified into two groups: those with £ 7 follicles 
measuring £ 12 mm and those with > 7 follicles measuring 2: 12 mm. On 
average, a lower number of embryos were transferred in patients in whom a 
lower number of follicles were detected than in patients with higher numbers 
of follicles (3.65 + 0.28 for <, 7 follicles vs. 4.00 + 0.71 for > 7 follicles). 
Table 9 summarizes hMG/FSH administration in tubal disease patients 
who subsequently became pregnant, as a function of the number of follicles 
measuring > 12 mm in diameter on the day of hCG administration. 
Although the lengths of hMG/FSH administration in the stratified subgroups 
were approximately the same, those patients producing less follicles (< 7) 
received a slightly smaller total dose of hMG/FSH than those patients 
producing a larger number of follicles (> 7). 
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VI. DISCUSSION 
The data analyzed in this study suggest that different ovarian responses 
to ovulation induction may affect success rates of IVF-ET in individual 
diagnostic groups. In particular, the study has demonstrated a strong inverse 
correlation between the success rate of IVF-ET in patients with tubal disease, 
the number of preovulatory follicles, and the level of estradiol measured on 
the day of hCG administration. 
In this study, the number of follicles measuring >12 mm in diameter 
has been established as a significant predictor of IVF-ET outcome in tubal 
disease patients. Having identified the inverse correlation between number 
of follicles detected by ultrasound and pregnancy rate, a cutoff point of 7 
follicles was selected for stratification, creating two tubal disease subgroups, 
those with < 7 follicles and those with > 7 follicles. In these patients, a 
striking decline in pregnancy rate was observed, from 28.3% in those with <, 7 
follicles to 8.7% in patients with > 7 follicles. Furthermore, with increasing 
numbers of follicles detected on ultrasound, a nearly linear descent in 
pregnancy rate occurred. Importantly, the higher pregnancy rate 
demonstrated for tubal disease patients with < 7 follicles measuring > 12 mm 
in diameter cannot be attributed to a higher number of transferred embryos. 
In fact, a smaller number of embryos were transferred in those patients with ^ 
7 follicles than in those with > 7 follicles. These findings extend prior 
observations made by Testart et al.^® and Forman et al.^9 Gf an inverse 
relationship between the number of preovulatory follicles and IVF-ET 
outcome in populations combining all infertility diagnoses. 
In a similar fashion, tubal disease patients in this study demonstrated a 
negative correlation between estradiol level measured on the day of hCG 
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administration and pregnancy rate. A significant decline in pregnancy rate 
was observed, from 28.9% in patients with estradiol levels <, 1,000 pg/ml to 
13.3% in those with estradiol levels > 1,000 pg/ml. Although this finding is 
statistically significant, estradiol levels appeared to be less predictive of IVF- 
ET outcome than number of follicles. As such, the estradiol level on the day 
of hCG administration may not represent an independent predictor of IVF-ET 
outcome; the inverse relationship between estradiol level and pregnancy rate 
may simply reflect the strong positive correlation observed in this study 
between the number of follicles produced and the estradiol level measured. 
Tubal disease patients who became pregnant were stimulated with the 
same average duration of gonadotropin therapy as those who did not become 
pregnant; despite this, those patients who became pregnant had lower 
estradiol levels, lower numbers of follicles detected, and lower numbers of 
oocytes retrieved than those who did not become pregnant. Moreover, of 
those patients with tubal disease who became pregnant, only slightly less 
gonadotropin stimulation was used in patients who produced <, 7 follicles 
than in patients with > 7 follicles. Patients with tubal disease who generated 
fewer follicles in response to ovulation induction produced oocytes with an 
increased probability of fertilization and embryos of higher quality, ultimately 
resulting in a greater likelihood of pregnancy. 
In general, patients in the "pure" tubal disease group are expected to 
have little or no other pathology involved in their infertility, with 
presumably normal ovarian and endometrial function. Therefore, the 
negative correlations observed between the number of follicles, the estradiol 
level, and pregnancy rate may be due to overstimulation of healthy, normally 
tuned ovaries and endometria, producing postmature oocytes, poor quality 
embryos, and suboptimal implantation. This hypothesis then suggests 
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possibilities for changes in the ovulation induction management of patients 
with tubal disease, including the earlier administration of hCG. In 
considering this explanation, it is essential to note that no difference in 
gonadotropin stimulation was detected between tubal disease patients who 
became pregnant and those who did not, or between pregnant patients with 
tubal disease who produced £ 7 follicles or > 7 follicles. These findings 
highlight a rather interesting divergence in ovarian response to similar levels 
of stimulation, rather than an identifiable difference in the stimulation 
protocol between those who did or did not achieve pregnancy. As such, 
ovarian and folllicular appearance during gonadotropin stimulation may be 
more helpful in predicting IVF-ET outcomes than in defining different 
stimulation regimens. Prospective randomized studies assigning tubal 
disease patients to different ovulation induction protocols may be helpful in 
resolving this issue. 
In addition to the findings demonstrated for tubal disease patients, the 
data analyzed in this study revealed trends in ovarian response and success of 
IVF-ET for other etiologies of infertility. Pregnancy rates for the general 
population correlated poorly with the number of follicles and the level of 
estradiol detected, contrasting with the significant inverse correlation 
between preovulatory follicles and IVF-ET outcome demonstrated by Forman 
et al.49 for the general population. It is possible that the Forman study 
population, of undefined composition in the literature, may have included 
patients diagnosed largely with tubal disease. The study by Testart et al.48 
tended toward a decreased proportion of pregnancies with increased numbers 
of follicles, although this result was not statistically significant. 
In contrast to patients with tubal disease, those with PCO or 
unexplained infertility had increased pregnancy rates with increased numbers 
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of follicles measuring ^ 12 mm on the day of hCG administration. After 
stratifying subgroups by estradiol level, only the unexplained infertility group 
continued to display increased pregnancy rates with increased estradiol. In 
patients with a diagnosis of PCO, the endocrine manipulations inherent in 
ovulation induction may partially correct the underlying ovarian pathology 
contributing to infertility. As such, increased levels of estradiol, while 
generating increased numbers of follicles, may preselect those follicles of 
higher quality. This possibility is further substantiated by the positive 
correlation observed between numbers of follicles detected and percentage of 
oocytes fertilized. In the case of unexplained infertility, although the actual 
cause remains unknown, occult endometrial factors are suspected to play a 
pathophysiologic role; therefore, the presence of inadequate or delayed 
endometrial maturation in a patient with unexplained infertility might be 
partially corrected by controlled ovarian hyperstimulation, yielding more 
favorable conditions for implantation and pregnancy with higher estradiol 
levels. Neither the endometriosis nor the male factor groups showed distinct 
patterns in relation to numbers of preovulatory follicles or estradiol levels. 
Although the trends in IVF-ET outcome displayed by these different 
diagnostic groups were not statistically significant, their elucidation 
introduces the possibility of an optimal ovarian response, range of pretransfer 
parameters, and probability of success for each etiology of infertility. 
A significant limitation of this study lies in the relatively small 
numbers of patients with "pure" diagnoses. Patients with multiple 
concurrent diagnoses comprised nearly one-half of the studied population. 
Among individual diagnostic groups, only the patients with tubal disease 
were well represented, with the remaining diagnostic groups numbering 28 to 
36 patients each. Thus, further studies need to be performed on larger 
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numbers of patients in individual diagnostic categories in order to increase 
the power of statistical analysis. Such studies may demonstrate the optimal 
number of preovulatory follicles or level of estradiol more convincingly for 
diagnoses other than tubal disease. 
The tubal disease population analyzed in this study represents only one 
population from one IVF center. Other populations from centers outside of 
this institution may be helpful in broadening the scope and applicability of 
the study findings. 
The evaluation of egg donor cycles may allow the dissociation of 
ovarian and endometrial factors involved in the IVF-ET outcome. In donor 
cycles, only the donor ovaries are exposed to the high estradiol levels 
associated with ovulation induction protocols; patients receiving the embryo 
transfers are each given standard doses of exogenous estradiol. By controlling 
for post-transfer hormone levels, such studies would allow the identification 
of endometrial contributions to IVF-ET outcome. 
Further analysis of the data may be performed with more sophisticated 
statistical tools. Logistic regression would allow a more precise delineation of 
those variables acting as independent predictors of outcome and those that 
have no independent predictive value. 
In summary, this study has elucidated distinct patterns of ovarian 
response and IVF-ET outcome in individual diagnostic categories, providing 
exciting insight into ovarian function in controlled hyperstimulation. Two 
easily obtainable IVF parameters, the number of follicles measuring ^12 mm 
and the level of estradiol measured on the day of hCG administration, have 
been identified as important predictors of outcome in patients with tubal 
disease and possible indicators of outcome in patients with other diagnoses. 
While the current practice of most IVF centers is to maximize the generation 
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of ovulatory size follicles in the hope of obtaining a large number of mature 
oocytes, the findings of this study bring into question whether this is actually 
beneficial for patients of specific diagnostic groups, and in particular, for 
patients with tubal disease. The emergence of this information necessitates 
the development of diagnosis-specific pretransfer parameters and 
individualized ovulation induction protocols in order to optimize the 
chances of pregnancy in patients with different etiologies of infertility. 
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Table 1. Distribution of the Population by Type of Cycle 
Population 
Age 
mean (range) 
Number of 
Cycles 
Number of 
Women 
Natural Cycle 35.4 (28-42) 18 9 
Egg Donor Cycle 35.6 (23-44) 5 5 
Sperm Donor Cycle 38.7 (31-42) 16 10 
Stimulated Cycle 34.6 (24-45) 466 184 

43 
4% 4% 
□ Natural Cycles 
Stimulated Cycles 
Sperm or Egg Donor Cycles 
92% 
Figure 1. Distribution of the population by type of cycle (N=505 cycles). 
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Table 2. Distribution of the Population by Diagnosis 
Population 
Age 
mean (range) # Cycles # Women 
General 34.6 (24-45) 466 184 
Tubal Disease 33.2 (24-42) 106 45 
PCO 32.0 (25-43) 34 17 
Endometriosis 33.8 (29-43) 36 12 
Male Factor 37.7 (29-44) 28 14 
Unexplained 35.6 (30-40) 36 13 

Figure 2. Distribution of the population by diagnosis. 
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Table 3. Distribution of Stimulation Protocols in the General Population 
Stimulation Protocol 
Age 
mean (range) 
Number of 
Cycles 
Number of 
Women 
hMG 33.7 (24-44) 89 50 
FSH 32.4 (25-39) 13 9 
hMG + FSH 35.5 (28-43) 2 2 
Lupron + hMG 34.8 (26-45) 238 130 
Lupron + FSH 34.9 (25-44) 61 50 
Lupron + 
hMG/FSH 
33.3 (25-38) 8 6 
Lupron Flare + 
hMG 
36.9 (30-43) 19 14 
Lupron Flare + 
FSH 
38.0 (38-38) 1 1 
Lupron Flare + 
hMG/FSH 
32.7 (31-36) 3 2 
Clomid 37.0 (34-40) 2 2 
Clomid + hMG 33.7 (27-38) 27 11 
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Figure 3. Pregnancy rates in individual diagnostic groups. Each bar 
represents the mean + SEM. 
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12 
Figure 4. Number of follicles measuring > 12 mm. on the day of hCG 
administration in individual diagnostic groups. Each bar represents the 
mean + SEM. 
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Figure 5. Estradiol levels in individual diagnostic groups. Each bar 
represents the mean + SEM. 
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Figure 6. Pregnancy rate by diagnosis as a function of the number of 
follicles measuring >12 mm on the day of hCG administration. Patients in 
all diagnostic categories were divided into two subgroups based upon the 
number of follicles detected. Each bar represents the mean + SEM. The 
asterisk denotes a significant difference in the means for Tubal Disease 
(P = 0.014) 
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Figure 7. Pregnancy rate by diagnosis as a function of the estradiol level 
measured on the day of hCG administration. All diagnostic categories were 
divided into two subgroups based upon the estradiol level measured. Each 
bar represents the mean + SEM. The asterisk denotes a significant difference 
in the means for Tubal Disease (P = 0.049) 
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Figure 8. Effect of the number of follicles >12 mm. on the day of hCG 
administration on the pregnancy rate in (A) the General population (N=466) 
and (B) the Tubal Disease population (N=106). 
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Table 8. IVF Parameters by Pregnancy Outcome for Tubal Disease 
Population 
Pregnancy 
Variable Yes No 
Age 33.4 + 0.9 33.1 ±0.6 
Days of hMG/FSH (#) 8.7 ±0.5 8.8 ±0.2 
Ampoules of hMG/FSH (#) 29.6 + 2.3 29.0 ±1.0 
Estradiol 1233 ±217 1492 ±114 
Follicles > 12 mm (#) 5.9 ± 0.6* 7.7 ±0.3 
Follicles >16 mm (#) 2.6 ± 0.4 3.4 ± 0.2 
Oocytes (#) 7.0 ± 0.9 8.4 ± 0.6 
Oocytes Fertilized (#) 5.1 ± 0.5 6.0 ± 0.5 
Oocytes Fertilized (%) 80.1 ±4.1 73.0 ±3.1 
Embryos Transferred (#) 3.7 ±0.3 3.7 ±0.2 
Embryos Transferred (Grade) 1.5 ± 0.1** 2.0 ±0.1 
* p = 0.017 
p = 0.007 
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Number of Follicles 
Figure 9. Number of transferred embryos in pregnant patients with 
Tubal Disease, as a function of the number of follicles measuring ^ 12 
mm in diameter on the day of hCG administration. Each bar 
represents the mean + SEM. 

59 
Table 9. hMG/FSH Administration in Pregnant Tubal Disease Patients 
Number of Follicles ^ 12 mm 
Variable <, 7 >7 
Days of hMG/FSH (#) 29.5 ± 2.8 30.0 ± 3.5 
Ampoules of hMG/FSH (#) 8.6 ± 0.5 9.3 ± 0.9 
Data are presented as the mean ± SEM. 
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